Article · 2013
Editor-in-Chief
Jerzy Jankun
Professor, The University of Toledo, USA
About
As published by the journal they serve.
Dr. Jerzy Jankun is the founding Director of Urology Research Center and Professor at Department of Urology, at Health Science Campus of University of Toledo. URC scientific research interest concentrates on proteolysis and different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth. Additionally inhibitors of proteolysis can reduce cancer spread. Special interest includes modified proteins to be used in therapy. That includes plasminogen activator type 1 with very long half-life (VLHL PAI-1) and modified human lipoxygenase.In the past laboratory explored photodynamic therapy to eradicate prostate and other cancers using small molecular weight photosensitizers and sensitizers conjugated with antibodies in targeted photodynamic cancer therapy (PDT). Dr. Jerzy Jankun’s research interest concentrates on proteolysis and different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth
Qualifications
PhD
Journals they serve
The seats these journals name them in.
- Andrology-Open AccessEditor-in-Chief
Articles we hold
Articles in the journals they serve whose byline carries this name.
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
